Show simple item record

dc.contributor.authorAtakan, Nilguen
dc.date.accessioned2019-12-10T10:52:27Z
dc.date.available2019-12-10T10:52:27Z
dc.date.issued2008
dc.identifier.issn1019-214X
dc.identifier.urihttps://doi.org/
dc.identifier.urihttp://hdl.handle.net/11655/14544
dc.description.abstractFor many years psoriasis was thought to be an epidermal disorder resulting from uncontrolled hyperproliferation of keratinocytes. After the discovery of T cell targeted immunosuppressive agents improving psoriasis, it has been considered as a T cell mediated autoimmune disease. Systemic agents including methotrexate, tretinoin, cyclosporin have been used to treat psoriasis for over 30 years. The understanding of psoriasis as a T-cell mediated disease has led to the development of biologic agents which target key molecules in the pathologic process. These new agents named biologicals appear to be safer than the agents in traditional therapies. Because they are so new and their long term safety is not established well; scientists are exploring several new therapeutic targets. Several new molecules such as angiogenesis inhibitors, immunomodulatory compounds, intracellular messenger targets, anti-inflammatory molecules, anti-integrins can be possible future treatment agent of psoriasis. (Turkderm 2008; 42 Suppl 2: 56-9)
dc.language.isotur
dc.publisherTurkish Soc Dermatology Venerology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDermatology
dc.titlePsoriasiste Gelecek Tedavilertr_TR
dc.title.alternativeFuture Therapies of Psoriasistr_en
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalTurkderm-Archives Of The Turkish Dermatology And Venerology
dc.contributor.departmentDeri ve Zührevi Hastalıkları
dc.identifier.volume42
dc.identifier.startpage56
dc.identifier.endpage59
dc.description.indexWoS


Files in this item

This item appears in the following Collection(s)

Show simple item record